QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

$64.43
-0.03 (-0.05%)
(As of 04:00 PM ET)
Today's Range
$64.42
$64.48
50-Day Range
$28.41
$64.50
52-Week Range
$6.71
$64.57
Volume
2.46 million shs
Average Volume
1.89 million shs
Market Capitalization
$4.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.33

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
21.9% Downside
$50.33 Price Target
Short Interest
Healthy
8.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Alpine Immune Sciences in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.74) to ($1.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.50 out of 5 stars

Medical Sector

690th out of 914 stocks

Pharmaceutical Preparations Industry

314th out of 416 stocks

ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

ALPN Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume
Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
Alpine Immune Sciences (NASDAQ:ALPN) Shares Gap Up to $47.04
Alpine Immune Sciences soars on $4.9bn Vertex takeover
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.33
High Stock Price Target
$65.00
Low Stock Price Target
$18.00
Potential Upside/Downside
-21.9%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-54.49%

Debt

Sales & Book Value

Annual Sales
$58.88 million
Book Value
$5.64 per share

Miscellaneous

Free Float
37,820,000
Market Cap
$4.22 billion
Optionable
Optionable
Beta
1.14
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price target for 2024?

11 brokers have issued 1 year price objectives for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $65.00. On average, they expect the company's stock price to reach $50.33 in the next year. This suggests that the stock has a possible downside of 21.9%.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 on January 1st, 2024. Since then, ALPN stock has increased by 238.2% and is now trading at $64.47.
View the best growth stocks for 2024 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 5,280,000 shares, a decrease of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is presently 4.4 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings results on Monday, March, 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.47. The biotechnology company had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%.

What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Banque Cantonale Vaudoise (0.03%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALPN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners